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Abstract
Background: Prednisone (PDN) in juvenile dermatomyositis (JDM), alone or in association with other
immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represents the first-line treatment
option for new onset JDM patients. No clear evidence based guidelines are actually available to standardize the
tapering and discontinuation of glucocorticoids (GC) in JDM. Aim of our study was to provide an evidence-based
proposal for GC tapering/discontinuation in new onset juvenile dermatomyositis (JDM), and to identify predictors of
clinical remission and GC discontinuation.
Methods: New onset JDM children were randomized to receive either PDN alone or in combination with
methotrexate (MTX) or cyclosporine (CSA). In order to derive steroid tapering indications, PRINTO/ACR/EULAR JDM core
set measures (CSM) and their median absolute and relative percent changes over time were compared in 3 groups.
Group 1 included those in clinical remission who discontinued PDN, with no major therapeutic changes (MTC)
(reference group) and was compared with those who did not achieve clinical remission, without or with MTC (Group 2
and 3, respectively). A logistic regression model identified predictors of clinical remission with PDN discontinuation.
Results: Based on the median change in the CSM of 30/139 children in Group 1, after 3 pulses of methyl-prednisolone,
GC could be tapered from 2 to 1mg/kg/day in the first two months from onset if any of the CSM decreased by 50–
94%, and from 1 to 0.2 mg/kg/day in the following 4months if any CSM further decreased by 8–68%, followed by
discontinuation in the ensuing 18months. The achievement of PRINTO JDM 50–70-90 response after 2 months of
treatment (ORs range 4.5–6.9), an age at onset > 9 years (OR 4.6) and the combination therapy PDN +MTX (OR 3.6)
increase the probability of achieving clinical remission (p < 0.05).
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Conclusions: This is the first evidence-based proposal for glucocorticoid tapering/discontinuation based on the
change in JDM CSM of disease activity.
Trial registration: Trial full title: Five-Year Single-Blind, Phase III Effectiveness Randomized Actively Controlled Clinical
Trial in New Onset Juvenile Dermatomyositis: Prednisone versus Prednisone plus Cyclosporine A versus Prednisone plus
Methotrexate. EUDRACT registration number: 2005–003956-37. Clinical Trial.gov is NCT00323960. Registered on 17
August 2005.
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Background
Juvenile dermatomyositis (JDM) is a rare, autoimmune dis-
ease, primarily characterized by muscle and skin involve-
ment. Less frequently, other systems like the
gastrointestinal tract or lungs may be affected. Beside the
significant decrease in the mortality rate of the disease in
the last years, due to the introduction of glucocorticoids
(GC) and disease modifying anti-rheumatic drugs
(DMARDs), disease and drug related morbidity are still a
major problem [1, 2]. Therapeutic approaches for adult pa-
tients with DM are not standardized [3–5], while those for
children are essentially based on consensus and literature
revision [6–10]. While GC still remain the mainstay of ini-
tial and long-term treatment in new-onset JDM despite
their known adverse effects, a still open question is how to
taper and discontinue GC in JDM patients. A recent ran-
domized trial in new-onset untreated JDM, conducted by
the Paediatric Rheumatology International Trials Organisa-
tion (PRINTO) [11, 12], showed that combined therapy
with prednisone (PDN) and either methotrexate (MTX) or
cyclosporine (CSA) was more effective than PDN alone.
The PRINTO trial foresaw a consensus plan for GC taper-
ing up to discontinuation which the participating centres
could follow in clinical practice for the children enrolled in
the study.
The primary objective of the present study was to pro-
vide an evidence-based proposal for GC tapering/discon-
tinuation in new onset JDM patients, through the
analysis of the PRINTO JDM trial. The secondary ob-
jective of the study was to identify predictors of GC dis-
continuation and clinical remission (CR) on medication.
Methods
Patients and study design
Data on new onset JDM children from the international,
multicentre, randomised, open label, superiority
PRINTO trial, whose details are available elsewhere,
were analysed [11, 13]. In brief, children aged 18 years or
younger, with newly diagnosed (PDN higher than 1mg/
kg for no more than 1month allowed) probable or def-
inite JDM, as per Bohan and Peter criteria [14, 15], were
included in the trial. Major exclusion criteria were the
presence of cutaneous or gastrointestinal ulceration or
JDM-related pulmonary disease or cardiomyopathy. Pa-
tients were considered untreated if they received one
month or less of PDN, no CSA or MTX.
Patients were randomized into 3 arms to either receive
PDN alone, PDN plus CSA (PDN + CSA), or PDN plus
MTX (PDN +MTX). The trial was divided into three
parts: induction (first 2 months), maintenance (22
months), and extension (at least 3 years). The study
database was locked after the last randomized patient
had completed the induction and maintenance phases.
The study was firstly approved by the ethics commit-
tees/institutional review board of the main centre in
Genoa, Italy (IRCCS Istituto Giannina Gaslini, Decision
nr. 77 of 09/02/2006) and then by those of all participat-
ing centres in the trial (54 centres in the following coun-
tries: Argentina, Belgium, Brazil, Czech Republic,
Denmark, France, Germany, Greece, Israel, Italy, La
Reunion, Latvia, Mexico, Netherlands, Norway, Serbia,
Slovakia, Slovenia, Sweden, United Kingdom, USA,
Venezuela).
Glucocorticoid tapering/discontinuation PRINTO protocol
Before randomization to one of the 3 aforementioned
arms, all children received three daily pulses of intra-
venous methylprednisolone (30 mg/kg per pulse, for a
maximum amount of 1 g per pulse). In the induction
phase, a consensus-based schema (NR, AR, AM and
PRINTO members) suggested to administer 2 mg/kg
per day of PDN or its equivalent (maximum 60mg/
day) divided in three doses per day (oral preferen-
tially) for 1 month, then moved to morning daily
dose, tapering the dose by 0.25 mg/kg every week to
reach a daily dose of 1 mg/kg per day at the end of
month 2. In the following 4 months PDN was sup-
posed to be gradually tapered, as long as the patient
remained clinically stable, up to a safe daily dose of
0.2 mg/kg by the end of month 6, which was main-
tained until the end of month 12. Afterwards, the
dose of PDN was reduced to 0.1 mg/kg per day for
further 6 months and then administered every other
day until month 24. If a patient reached the status of
inactive disease before month 24, PDN could be dis-
continued at physician’s discretion after discussion
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with the family. After the second year, treatment was
at the discretion of the treating clinician.
Assessment and outcome
Clinical assessments to define patients’ response to ther-
apy according to PRINTO criteria were performed every
two months in the initial 6 months (monthly for safety)
and then every 6 months up to year 2. Treatment failure
(TF) was defined as the addition of CSA or MTX or any
other DMARDs in any of the 3 groups or a major in-
crease in their dose, or major increase in PDN dose or
discontinuation of the assigned therapy for any reason
(adverse events [AE], lost to follow-up, etc.).
Children were defined as responders if they demon-
strated ≥20% (or 50/70/90%) improvement in ≥3 of the 6
variables of the JDM core set [16] with ≤1 variable wors-
ening by > 30% (muscle strength excluded) [17, 18]. The
6 validated JDM PRINTO/American College of Rheuma-
tology (ACR)/European League Against Rheumatism
(EULAR) disease activity core set variables were: [16]
the Childhood Myositis Assessment Scale (CMAS) (0 =
worst; 52 = best); [19] physician’s global assessment
(Physician global) of the patient’s overall disease activity
on a 0–10-cm visual analogue scale (VAS) (0 = best; 10
= worst); [20] the Disease Activity Score (DAS) (0 = best;
20 = worst); [21] the cross-culturally adapted and vali-
dated version of the Childhood Health Assessment
Questionnaire (C-HAQ) (0 = best; 3 = worst) [22, 23];
the parent’s global assessment of the child’s overall pa-
tient’s well-being (Parent Global) on a 10-cm VAS (0 =
very well; 10 = very poor) [20, 22, 23]; the parent version
of the physical summary score (PhS) of the Child Health
Questionnaire (CHQ) [23, 24], with lower score indicat-
ing worse quality of life.
Patients were classified as being in a status of inactive
disease if they met the validated PRINTO criteria for clin-
ically inactive disease, which means at least 3 out of the
following 4 criteria: creatine kinase ≤150, CMAS≥48,
Manual Muscle Testing (MMT) ≥78, and PhyGlo VAS ≤
0.2. We then verified our results through the proposed re-
vised criteria by Almeida et al., which require mandatory
PhyGlo VAS ≤ 0.2 [25, 26]. Clinical remission was defined
as a status of inactive disease maintained for 6 continuous
months on medication (clinical remission on medication)
or 12 continuous months off any DMARDs/glucocorti-
coids (clinical remission off medication) [25].
Children in the trial were subsequently categorized into
3 mutually exclusive groups. Group 1 represented the ref-
erence standard for the best clinical outcome defined as
those children on clinical remission on medication, with
no TF, and no major deviation (±0.2mg/kg PDN dose)
from the assigned GC protocol, and who could discon-
tinue PDN as per the suggested tapering schedule (CR
Yes-TF no-PDN off). Group 1 was compared with those
who did not achieve clinical remission, without TF (Group
2: CR no-TF no-PDN on or off) or with TF (Group 3: CR
no-TF yes-PDN on or off). (Fig. 1).
Statistical analysis
Baseline and follow-up characteristics were summarized
using descriptive statistics primarily by median (1st-3rd
quartiles) changes in the PRINTO core set measures
(CSM) in the first 6 and over 24 months. Proportions
were analyzed by chi-square, or Fisher’s Exact test while
for continuous variables t-test or ANOVA. Non para-
metric ANOVA (Kruskal-Wallis test to compare 3
groups and Friedman test to compare repeated measures
during time) has been applied in case of ordinal or
non-normally distributed variables. For multiple hypoth-
esis testing, Bonferroni’s correction was applied
([1-((1-p)n)], with n = 3 posterior comparisons).
For each core set variable, absolute change and “rela-
tive” percent change were calculated; the term “relative”
refers to the fact that whenever the measure assumed
the value of 0 at starting point, the percent change was
calculated taking into account the range of the scale (ex-
ample: the “relative” percent change of a measure chan-
ging from 0 to 2 on a 0–10 point-scale was equal to +
20% instead of the rough usual value of + 100%) [27].
When missing data occurred for spare data among the
different CSM, a mean value was calculated in case the
missing value was between two available time points.
The association between the change in each core set vari-
able, and the attainment of a status of GC discontinuation
or CR on medication, were analyzed by multiple logistic re-
gression, which used all significant variables in Table 1 and
the different levels of PRINTO criteria for response at
months 2, 4 and 6 to calculate the baseline-to-2-month
change and the baseline-to-6-month change in each core
set variable and as the dependent outcome clinical remis-
sion. Odds ratios (OR) with 95% confidence intervals (95%
CI) were reported. Continuous variables were dichotomized
according to the best cut-offs provided by the ROC analysis.
[28] The pre-analysis hypothesis was that children able to
demonstrate an earlier improvement in the PRINTO CSM
or PRINTO criteria of response were more likely to achieve
PDN discontinuation.
Data were entered into an Access XP database and an-
alyzed with Excel XP (Microsoft), XLSTAT 6.1.9 Addin-
soft, Statistica 6.0 (StatSoft, Inc), and Stata 7.0 (Stata
Corporation).
Results
As shown in Figs. 1, 139 children from 54 centres in
22 countries were enrolled and randomized in the
trial. Thirty (21.6%) patients were classified in Group
1 (CR yes-TF no-PDN off ), 43 (30.9%) in Group 2
(CR no-TF no/PDN on or off ), and 66 (47.5%) in
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Group 3 (CR no-TF yes/PDN on or off ). At baseline
all the three groups had a high level of disease activ-
ity with no differences in the CSM (Table 1). Age at
onset was the only variable with a statistically signifi-
cant difference at baseline among the three groups
with children in Group 1 (CR yes-TF no-PDN off )
showing an older age at onset (9.5 versus 6.5 versus
6.9, p = 0.016).
Most of the patients in Group 1 (15 pt., 50%) re-
ceived MTX + PDN, most of the patients in group 3
(30 pt., 45.5%) received PDN alone, while Group 2
was well balanced between the different drugs (9 pt. –
20.9% received PDN, 14 pt. – 32.6% PDN +MTX and
20 pt. – 46.5% PDN + CSA) in the middle (data not
shown).
Change over time in PRINTO core set measures
Figure 2 shows the trend over time of the PRINTO
CSM and MMT in the 3 groups. Already after 2 months
of treatment the 3 groups start to differentiate for all the
disease activity measures in comparison to baseline. A
statistically significant trend over time can be recognized
from month 4 especially between Group 1 (CR yes-TF
no-PDN off ) and Group 3 (CR no-TF yes-PDN on or
off ), in particular for MD global, parent global, DAS,
CMAS, MMT (all p values < 0.001) and CHAQ (p value
= 0.002), with the exception of PhS that is very close to
statistical significance and starts to be significant from
month 12 onward.
When we considered patients in inactive disease ac-
cording to the two different definitions (PRINTO criteria
Fig. 1 Study design. JDM juvenile dermatomyositis, PDN prednisone, MTX methotrexate, CSA cyclosporine, pts patients, CR clinical remission, TF
treatment failure
Table 1 Baseline characteristic and PRINTO core set measures at onset of the study population
Group 1
(CR yes-TF no-PDN off)
N = 30
Group 2
(CR no-TF no/PDN
on or off)N = 43
Group 3
(CR no-TF yes/PDN
on or off) N = 66
P*
Age at onset (years) 9.5 (6.2–12.3) 6.5 (3.3–9.8) 6.9 (4.2–10) 0.016
Disease duration (mo) 2.6 (1.3–4.7) 2.6 (1.3–6.4) 3.0 (1.5–4.8) 0.94
MD-global (0–10 ↑) 7.0 (6.0–8.0) 6.0 (5.0–7.0) 7.0 (5.0–8.0) 0.17
Parent global (0–10 ↑) 6.0 (5.0–8.0) 5.0 (3.5–7.0) 5.4 (5.0–7.0) 0.40
CHAQ (0–3 ↑) 1.8 (1.1–2.6) 1.8 (1.4–2.6) 1.9 (1.3–2.5) 0.94
DAS (0–20 ↑) 13.0 (11.0–15.0) 13.0 (11.0–15.0) 13.0 (11.0–15.0) 0.80
CMAS (0–52 ↓) 16.5 (13.0–33.0) 21.0 (14.0–35.0) 20.7 (11.0–32.0) 0.96
MMT (0–80 ↓) 40.0 (30.0–60.0) 47.0 (35.0–58.0) 48.0 (34.0–56.0) 0.84
CHQ PhS (40–60 ↓) 19.8 (9.4–33.4) 12.7 (5.2–23.5) 14.9 (8.1–22.4) 0.16
Data are medians (1st 3rdquartiles). *P: P value refers to the non-parametric Analysis of Variance (Kruskal-Wallis test); MD-global: physician’s global assessment of
the patient’s overall disease activity on a 0–10-cm visual analogue scale (VAS); Parent global: parents’ global assessment of the child’s overall patient’s well-being
on a 10-cm VAS; DAS Disease Activity Score; CMAS Childhood Myositis Assessment Scale, MMT manual muscle testing; CHAQ cross-culturally adapted and
validated version of the Childhood Health Assessment Questionnaire); ↑ indicates that higher values correspond to a worse outcome; ↓ indicates that lower values
correspond to a worse outcome
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Fig. 2 Trend of the PRINTO CSM and MMT in the 3 groups of children with JDM. [A =MD-global: physician’s global assessment of the patient’s
overall disease activity on a 0–10-cm visual analogue scale (VAS); B=Parent global: parents’ global assessment of the child’s overall patient’s well-
being on a 10-cm VAS; C = DAS: Disease Activity Score (range 0–20); D = CHAQ: cross-culturally adapted and validated version of the Childhood
Health Assessment Questionnaire (range 0–3); E = CMAS: Childhood Myositis Assessment Scale (range 0–52); F = MMT: manual muscle testing
(range 0–80); G = PhS: physical summary score of the Child Health Questionnaire (range 40–60)]
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[25] and Almeida’s criteria [26]), a complete overlap
could be identified, since all the 30 patients from Group
1 (CR yes-TF no-PDN off ) met both definitions having a
Physician VAS ≤ 0.2.
Analyzing in more details the first 6 months from
treatment start, while Groups 1 and 2 showed a similar
trend in the improvement of disease activity parameters
in the initial 2 to 6months, Group 2 was not able to
reach a status of clinical remission despite PDN being
discontinued in 31/43 (72%) of the patients. Group 3
was even more different since only 20/66 (30%) were
able to discontinue GC despite a TF which required a
major change in treatment to control disease activity pa-
rameters (Figs. 1 and 2).
Table 2 shows the analysis of the median absolute
change and relative percent change in disease activity pa-
rameters for the patients in the reference Group 1 (CR
yes-TF no-PDN off). The median change in the CSM of
Group 1 (CR yes-TF no-PDN off) was more pronounced
in the initial 6 months of treatment (Table 2). In particular,
an at least 50% change was present in all CSM already at
month 2, with a marked CMAS change rising to 94% at
month 2, and MD-global, MMT or DAS change of at least
3, 20 and 7 units, respectively. After 2months from
randomization and treatment start, the change in CSM
became much less pronounced, with stable values after 6
months. With respect to the range of the scale for each
core set variable, there was a considerable relative percent
change in the different CSM over time (Table 2).
Predictors of glucocorticoid discontinuation in children
with clinical remission on medication
The logistic regression model, including age at onset
(the only statistically significant variable in Table 1), and
the different levels of PRINTO criteria for response at
months 2, 4 and 6, showed that the achievement of a
PRINTO JDM 50–70-90 response at 2 months (OR
range 4.5–6.9) from treatment start, an age at onset > 9
years (OR 4.6) and the combination therapy PDN +
MTX (OR 3.6) increase the probability of achieving CR
(p < 0.05) (Table 3).
The PRINTO evidence-based glucocorticoid tapering/
discontinuation proposal
Figure 3 shows the PRINTO evidence-based treatment
plan for GC tapering/discontinuation in children with new
onset JDM. In brief, after 3 pulses of methyl-prednisolone,
PDN could be tapered from 2 to 1mg/kg/day in the first
two months from onset if any of the CSM decrease by at
least 50%, and from 1 to 0.2mg/kg/day in the following 4
months if any of the CSM decreases further by 8–68%,
followed by discontinuation over the next 18months.
All children in group l followed the PDN consensus
protocol for tapering treatment, as opposed to 5/43
(11.6%) and 50/60 (75.8%) in groups 2 and 3, respectively.
Discussion
The PRINTO JDM trial was a randomized study with a
considerable number of new-onset JDM patients suited to
provide an evidence-based proposal for GC tapering/dis-
continuation. It demonstrated that the use of combined
therapy, MTX+ PDN, is the best treatment option in these
patients in terms of safety and efficacy. The PRINTO
consensus-based steroid tapering protocol proposed in the
randomized trial was tested against the strongest outcome
of clinical remission off GC to extrapolate an
evidence-based proposal for GC tapering/discontinuation.
Table 2 24 month-change in the PRINTO Core Set Measures in Reference Group 1 (N = 30)
0 months 0–2 months Absolute
change (% change)
2–4 months Absolute
change (% change)
4–6 months Absolute
change (% change)
6–24 months Absolute
change (% change)
MD evaluation (0–10 ↑) 7 -3
(− 66.7%)
−1
(− 68.3%)
0
(0%)
0
(0%)
DAS (0–20 ↑) 13 −7
(− 50%)
−2
(− 40%)
−1
(− 33.3%)
−1
(− 6.5%)
CMAS (0–52 ↓) 16.5 + 16
(+ 93.8%)
+ 4
(+ 15.8%)
+ 1
(+ 2.0%)
+ 1
(+ 3.4%)
MMT (0–80 ↓) 40 + 20
(+ 53.8%)
+ 6
(+ 8.1%)
+ 1.5(+ 2.1%) + 1
(+ 1.3%)
Parent global (0–10 ↑) 6 −4
(− 76.4%)
0
(0%)
0
(0%)
0
(0%)
CHAQ (0–3 ↑) 1.8 −1.2
(−82.5%)
−0.1
(− 28.6%)
0
(0%)
0
(0%)
PhS (40–60 ↓) 19.8 + 14.2 (+ 53.8%) + 8.4 (+ 21.1%) +3.2 (+ 7.3%) + 1.9 (+ 4.3)
Group 1: clinical remission yes- treatment failure no- prednisone off. MD-global: physician’s global assessment of the patient’s overall disease activity on a 0–10-cm
visual analogue scale (VAS); Parent global: parents’ global assessment of the child’s overall patient’s well-being on a 10-cm VAS; DAS Disease Activity Score, CMAS
Childhood Myositis Assessment Scale, MMT manual muscle testing, CHAQ cross-culturally adapted and validated version of the Childhood Health Assessment
Questionnaire; ↑ indicates that higher values correspond toa worse outcome; ↓indicates that lower values correspond to a worse outcome
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At baseline, disease activity was comparable in all the
three groups of patients analyzed, but the group of pa-
tients with an older age showed a better outcome as
confirmed by the logistic regression model. After treat-
ment initiation, the three groups significantly differenti-
ated over time, with a clear trend given by a sharp
decrease in disease activity parameters, which was par-
ticularly evident when the reference Group 1 was com-
pared with the other two groups. Most important, the
differentiation in disease activity started very early
(already after 2 months), and became apparent within
the first 6 months of observation. This means that a
trend toward a fast decrease in disease activity parame-
ters can be recognizable in the early phase of treatment
and can be used as clinical predictor of a better out-
come. While group 1 and 2 showed a similar trend in
the decrease of disease activity parameters in the initial
2 to 6 months, they represent a different clinical pheno-
type according to clinical remission, so they could not
be combined. Group 3 had the worst outcome since just
one third was able to discontinue glucocorticoids, but
with the need to introduce a major change in treatment
to control disease activity.
The analysis was therefore focused on Group 1 (CR yes,
TF no, PDN off), as the reference standard group in the
trial population. Indeed this group showed a greater im-
provement in disease activity, which was already evident
after 2months. Based on the observation of this group, we
could provide an evidence-based proposal on how to taper
prednisone, up to discontinuation, in new onset JDM pa-
tients using quantitative cut-offs of CSM, that foresee a
rapid decrease in few months to the dose of PDN which is
thought to limit effects on growth [29]. Indeed, the know-
ledge of lower cut-offs for the single core set parameters,
whose achievement may allow the clinician to modify
therapy, is a practical indicator for the physician who has
to decide in the everyday clinical practice how to use the
JDM outcome measures to taper GC.
In the last years, literature provided consensus-based
recommendations, aimed to facilitate diagnosis and
Table 3 Predictors of clinical remission and prednisone
discontinuation
Odds Ratio (95% CI) p#
Responder at 2 months:
Printo-50
(vs. not responder/Printo-20)
5.41 (1.37–21.32) 0.0076
Printo-70
(vs. not responder/Printo-20)
6.90 (1.91–24.99)
Printo-90
(vs. not responder/Printo-20)
4.46 (1.08–18.38)
Onset age > 8.53 years
(vs. ≤ 8.53 years)
4.64 (1.69–12.71) 0.0017
Therapygroup: PDN +MTX
(vs. PDN/PDN + CSA)
3.63 (1.30–10.09) 0.0116
AUC of the model 0.80
PDN prednisone, MTX methotrexate, CSA Cyclosporine. OR Odds Ratio, 95% CI
95% Confidence Interval; p#: Likelihood Ratio test
Fig. 3 PRINTO evidence-based proposal for PDN tapering/discontinuation in a 2-year time frame
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treatment of JDM patients through multiple meetings
among clinicians and researchers. In this context the
Children’s Arthritis and Rheumatology Research Alliance
(CARRA) proposed consensus treatment plans for the
management of JDM patients with recent onset [9, 30].
The use of GC in JDM was a main point of the consen-
sus, with the specialists providing indications on the
timing and modality of steroid tapering and use. Despite
the longest period for GC discontinuation proposed by
this study, and differently from the CARRA recommen-
dation, we think that it can be a valuable option for GC
tapering/discontinuation due to the evidence of strong
outcome (clinical remission off GC) in the PRINTO
cohort, the already reported acceptable safety profile
[11, 12], and the possibility to achieve after only 6
months the safe dose of 0.2 mg/kg/day, so avoiding
long PDN exposure and subsequent side effects. More-
over, the PRINTO JDM trial represents a large source of
prospective data on a very rare condition in pediatrics,
which still needs to be clarified in multiple aspects. This
allows observations on real patients’ data with the advan-
tage of reporting evidence-based information. Differently
from CARRA recommendations, nevertheless, our treat-
ment plan provides evidence that it is possible to achieve
the steroid dose of 0.2 mg/kg/day, considered safer espe-
cially for growth impairment, within 6months instead of
9, with good clinical control, so avoiding long PDN expos-
ure and subsequent side effects. In 2016, a similar effort,
conducted by a European initiative called Single Hub and
Access point for pediatric Rheumatology in Europe
(SHARE) initiated in 2012 to provide diagnostic and
therapeutic regimens for all the pediatric rheumatic dis-
eases, yielded, through a consensus process, recommenda-
tions on diagnosis and therapy in JDM, including
consensus on steroid use, to be reduced as the patient
shows clinical improvement [10]. The PRINTO proposal
for tapering will allow pediatric rheumatologist to take ad-
vantage of concrete quantitative indications about how to
use GC and when and how to taper them in clinical
practice based on the change in individual CSM. The
importance of evaluating quantitatively CSM in the
JDM patient follow-up is consequently a major point
and should be performed by all the pediatric rheuma-
tologists at each visit [16–18, 31–40].
The results of this study are important also in light
of future treatment plans which apply a
treat-to-target strategy, already proposed in the man-
agement of juvenile idiopathic arthritis (JIA) [41]. In-
deed, the identification that the attainment of at least
JDM PRINTO 50 criteria of response in 2 months or
an improvement by at least 50% in CSM (90% in
CMAS), especially in children treated with the com-
bination of PDN +MTX, is a very early predictor of
clinical remission and steroid discontinuation, favors
the hypothesis that earlier and more aggressive treat-
ment might lead to a better outcome. The results of
this study might allow the pediatric rheumatologists
to tell patients and families if there is a higher prob-
ability of achieving remission according to the course
of the disease in the first months from treatment
start. Looking from a different perspective a patient
without these characteristics could be considered at
higher risk of a worse disease course and deserve
therefore more aggressive treatments.
This work has some limitations that should be consid-
ered by the pediatric rheumatologist, willing to follow
our proposal. First of all, a limitation of our study may
be represented by the long period of administration of
steroids, whose side effects may prevent the use of this
medication. Nevertheless, the cumulative dose of PDN
per kilo of body weight was 250.88 mg for both group 1
and 2, and 250.9 for group 3, (data not shown) which
means that the cumulative dose of GC was similar for
all the three groups, not modifying the PDN-related side
effects. Moreover, this steroid schedule allows to reach
what is considered in all trials in poly-articular course
JIA a safer dose of PDN (0.2 mg/kg/day or 10mg/day
whichever is lower) [42–46], in a short time (6 months),
continuing just with a very low dose up to month 24,
when discontinuation may be attempted. Finally, in an
independent PRINTO series of 275 patients collected
worldwide, 41/98 (41.8%) of children with recent onset
JDM were still on glucocorticoid treatment after 24
months from disease onset. [5]
Up to now, we cannot compare our results with other
randomized trials on steroid tapering/discontinuation in
new- onset JDM patients. The lack of alternative steroid
protocols, provided by evidence-based trials, or standard
consensus on glucocorticoid therapy for both intraven-
ous and oral induction, does not allow further consider-
ations about safety and efficacy of the proposed steroid
tapering schedule neither comparison with a shorter
steroid course, likely to be considered preferable. Since
the purpose of the present work was not to provide rec-
ommendations on the use of glucocorticoids in JDM,
but to propose a possible protocol for glucocorticoids ta-
pering withdrawal in new-onset JDM patients, the pro-
posed protocol may help the pediatric rheumatologist to
deal at onset with such a challenging disease.
Another major point of discussion is the presence of
around 50% of patients in Group 1 on PDN+MTX, which
is the most effective treatment group in the PRINTO JDM
trial [11]. This could have induced an improvement in dis-
ease activity, not due to the proposed glucocorticoid tapering
protocol, but to the combination therapy with MTX as also
underlined by the logistic regression model. It should be
noted, however, that one third of patients in the other two
groups, received the same combination of PDN+MTX.
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Another limit of the present work is the small com-
parative sample size and reference group. However this
should be read in light of the rarity of the disease and
the lack of prospective data on new onset JDM patients
which makes our results noteworthy.
Finally, it is notable that a large percentage of patients
(42%) failed to discontinue GC according to the pro-
posed weaning schedule. If we consider that all the three
groups of patients presented at baseline with the same
demographic and clinical features (Table 1), except for a
slightly increased disease duration in Group 3, and since
MTX therapy is well-proven in efficacy in JDM patients
[11], this should be read as a warning in considering
MTX at the very beginning of the JDM patient history.
The lack of change in the CSM after 12 months in
Group 1 and 2 in particular may raise the need of new
trials testing two different strategies for steroid tapering
with the main aim to shorten the on-therapy period. In
fact, in order to either confirm our results or propose
new treating strategies in new onset JDM patients, there
is the new of new comparative studies in pediatrics.
Conclusions
This study provides a steroid tapering plan in new-onset
JDM patients. In particular, we propose evidence-based
specific quantitative cut-offs for glucocorticoids taper-
ing/discontinuation based on the change in the CSM in
the initial 6 months of treatment as well as in the overall
response to treatment and we identify early predictors of
remission, to be used in daily practice and in future clin-
ical trials by pediatric rheumatologists.
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